{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:06:26Z","timestamp":1774443986525,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s10555-013-9466-0","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T10:24:56Z","timestamp":1390386296000},"page":"361-366","source":"Crossref","is-referenced-by-count":5,"title":["Pancreatic NETs: where do we stand now?"],"prefix":"10.1007","volume":"33","author":[{"given":"S.","family":"Faivre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"key":"9466_CR1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(68)91058-1","volume":"2","author":"IM Murray-Lyon","year":"1968","unstructured":"Murray-Lyon, I. M., et al. (1968). Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet, 2, 895\u2013898.","journal-title":"Lancet"},{"key":"9466_CR2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","volume":"79","author":"LE Broder","year":"1973","unstructured":"Broder, L. E., & Carter, S. K. (1973). Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Annals of Internal Medicine, 79, 108\u2013118.","journal-title":"Annals of Internal Medicine"},{"key":"9466_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-79-1-101","volume":"79","author":"LE Broder","year":"1973","unstructured":"Broder, L. E., & Carter, S. K. (1973). Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Annals of Internal Medicine, 79, 101\u2013107.","journal-title":"Annals of Internal Medicine"},{"key":"9466_CR4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","volume":"303","author":"CG Moertel","year":"1980","unstructured":"Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980). Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine, 303, 1189\u20131194.","journal-title":"New England Journal of Medicine"},{"key":"9466_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"CG Moertel","year":"1992","unstructured":"Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine, 326, 519\u2013523.","journal-title":"New England Journal of Medicine"},{"key":"9466_CR6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","volume":"86","author":"PN Cheng","year":"1999","unstructured":"Cheng, P. N., & Saltz, L. B. (1999). Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer, 86, 944\u2013948.","journal-title":"Cancer"},{"key":"9466_CR7","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"MA Kouvaraki","year":"2004","unstructured":"Kouvaraki, M. A., et al. (2004). Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology, 22, 4762\u20134771.","journal-title":"Journal of Clinical Oncology"},{"key":"9466_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke, M. H., et al. (2006). Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology, 24, 401\u2013406.","journal-title":"Journal of Clinical Oncology"},{"key":"9466_CR9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2011","unstructured":"Strosberg, J. R., et al. (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117, 268\u2013275.","journal-title":"Cancer"},{"key":"9466_CR10","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","volume":"30","author":"JA Chan","year":"2012","unstructured":"Chan, J. A., et al. (2012). Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 30, 2963\u20132968.","journal-title":"Journal of Clinical Oncology"},{"key":"9466_CR11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke, M. H., et al. (2009). O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research, 15, 338\u2013345.","journal-title":"Clinical Cancer Research"},{"key":"9466_CR12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond, E., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364, 501\u2013513.","journal-title":"New England Journal of Medicine"},{"key":"9466_CR13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao, J. C., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine, 364, 514\u2013523.","journal-title":"New England Journal of Medicine"},{"key":"9466_CR14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao, Y., et al. (2011). DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331, 1199\u20131203.","journal-title":"Science"},{"key":"9466_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia, E., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28, 245\u2013255.","journal-title":"Journal of Clinical Oncology"},{"key":"9466_CR16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","volume":"17","author":"GM Blumenthal","year":"2012","unstructured":"Blumenthal, G. M., et al. (2012). FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. The Oncologist, 17, 1108\u20131113.","journal-title":"The Oncologist"},{"key":"9466_CR17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","volume":"303","author":"D Bassler","year":"2010","unstructured":"Bassler, D., et al. (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303, 1180\u20131187.","journal-title":"JAMA"},{"key":"9466_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jama.2010.933","volume":"304","author":"SS Ellenberg","year":"2010","unstructured":"Ellenberg, S. S., DeMets, D. L., & Fleming, T. R. (2010). Bias and trials stopped early for benefit. JAMA, 304, 158\u2013159. 158; author reply.","journal-title":"JAMA"},{"key":"9466_CR19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre, S., et al. (2006). Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology, 24, 25\u201335.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-013-9466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-013-9466-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-013-9466-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:20:12Z","timestamp":1559236812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-013-9466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["9466"],"URL":"https:\/\/doi.org\/10.1007\/s10555-013-9466-0","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]}}}